Stem Cell Therapy for Ulcerative Colitis
What this article covers
- What This Article Covers
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can be difficult to control even with biologics, and some patients don't respond to any approved drug. That treatment gap has pushed researchers to test mesenchymal stem cells (MSCs) as a way to quiet the immune overactivity driving UC flares.
- How It's Thought to Work
- MSCs don't appear to regenerate colon tissue directly. Instead, research suggests they act like immune "conductors" — releasing signals that dial down inflammatory cytokines and encourage regulatory immune cells that promote healing.
- What the Evidence Shows
- 2% still in remission at six months — genuinely promising numbers for a group that had already failed conventional treatment.
- Who Might Be a Candidate
- Right now, MSC therapy for UC exists only inside research studies — not as a standard or approved treatment option.
- Bottom Line
- The research on mesenchymal stem cells for ulcerative colitis is genuinely encouraging — remission and response rates in early trials exceed what many refractory patients see with standard therapy, and safety signals so far are reassuring. But "encouraging early trial" is not the same as "proven treatment": no MSC product is FDA-approved for UC, sample sizes remain small, and most results still need confirmation in larger, placebo-controlled studies.
What This Article Covers
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can be difficult to control even with biologics, and some patients don't respond to any approved drug. That treatment gap has pushed researchers to test mesenchymal stem cells (MSCs) as a way to quiet the immune overactivity driving UC flares. This article looks specifically at UC evidence — separate from Crohn's disease, which involves different trial data and is covered elsewhere on this site — and lays out what current studies actually show, where trials stand, and why no stem cell therapy is an approved treatment yet.
How It's Thought to Work
MSCs don't appear to regenerate colon tissue directly. Instead, research suggests they act like immune "conductors" — releasing signals that dial down inflammatory cytokines and encourage regulatory immune cells that promote healing. A 2024 study in Stem Cell Research & Therapy found that after umbilical cord MSC infusions, patients' levels of inflammatory markers (including IL-1β, IL-6, IL-8, and IL-17A) dropped substantially, while a protective marker ratio (IL-10/IL-17A) rose — a pattern consistent with the immune system shifting out of attack mode (Wei et al., 2024).
What the Evidence Shows
The most encouraging UC-specific data comes from that 2024 trial of 41 patients with moderate-to-severe, drug-refractory UC: 73.2% achieved a clinical response and 41.5% reached remission two months after two monthly IV infusions of umbilical cord MSCs, with 70.0% still showing a response and 34.2% still in remission at six months — genuinely promising numbers for a group that had already failed conventional treatment.
A 2019 systematic review and meta-analysis pooling 15 studies (7 human trials, 216 patients) found MSC therapy outperformed standard mesalamine (5-ASA) treatment and reported a 78.7% overall healing rate across single-arm human trials — though the authors were careful to note the studies were small and methodologically inconsistent (Lightner et al., Stem Cell Research & Therapy, 2019).
A Cleveland Clinic-led Phase Ib/IIa trial of remestemcel-L, an allogeneic bone marrow-derived MSC product injected directly into the colon during colonoscopy, reported that all 12 initial UC patients reached clinical and endoscopic remission by six weeks, alongside a marked drop in fecal calprotectin (a gut inflammation marker) — while placebo-treated patients got worse on the same measures (Lightner et al., Colorectal Disease, 2022). Trials like NCT04543994 continue to enroll medically refractory UC patients to test MSC infusions further (ClinicalTrials.gov). Across all this research, no serious treatment-related adverse events have been reported, though sample sizes remain small.
Who Might Be a Candidate
Right now, MSC therapy for UC exists only inside research studies — not as a standard or approved treatment option. People who may eventually be considered for a clinical trial include:
- Adults with moderate-to-severe UC that hasn't responded to biologics or conventional immunosuppressants
- Patients facing colectomy (surgical colon removal) who want to explore additional options first
- Those willing to enroll in an IRB-approved clinical trial with structured monitoring, rather than pay for treatment at a private clinic
- Patients in stable enough health to tolerate infusion- or colonoscopy-based procedures
- Anyone who discusses trial eligibility directly with a gastroenterologist or IBD specialist, ideally one affiliated with an academic research center
Bottom Line
The research on mesenchymal stem cells for ulcerative colitis is genuinely encouraging — remission and response rates in early trials exceed what many refractory patients see with standard therapy, and safety signals so far are reassuring. But "encouraging early trial" is not the same as "proven treatment": no MSC product is FDA-approved for UC, sample sizes remain small, and most results still need confirmation in larger, placebo-controlled studies. The FDA has separately warned that clinics selling unregulated "stem cell" treatments outside of legitimate trials carry real safety risks. For now, the most responsible path to this therapy is enrollment in a registered clinical trial, discussed with your IBD care team.
Key Questions Answered
- Is stem cell therapy approved for treating ulcerative colitis?
- No. As of 2026, there is no stem cell product approved by the FDA specifically for ulcerative colitis. The evidence comes from early-phase clinical trials, not an approved treatment you can request from your gastroenterologist.
- What kind of stem cells are being studied for UC?
- Nearly all research uses mesenchymal stem cells (MSCs), sourced from bone marrow, umbilical cord tissue, or fat. These cells aren't thought to regrow gut tissue directly — instead, researchers believe they release signals that calm an overactive immune response.
- How are the stem cells given?
- Trials have tested MSCs delivered intravenously (through an IV) and directly into the colon lining via injection during colonoscopy. Both approaches have shown safety and encouraging short-term results, but they haven't been directly compared head-to-head in large studies.
- Is it safe?
- In published trials, MSC infusions have generally been well tolerated, with mild, short-lived side effects like low-grade fever or fatigue and no serious treatment-related adverse events reported. That said, these trials have been small, and long-term safety data are still limited — this is separate from unregulated clinics offering unapproved "stem cell" injections, which carry real risks.
Sources
- Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms — Stem Cell Research & Therapy — 2024 — https://link.springer.com/article/10.1186/s13287-024-03878-y
- Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies — Stem Cell Research & Therapy — 2019 — https://link.springer.com/article/10.1186/s13287-019-1336-4
- A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis — Colorectal Disease (Wiley) — 2022 — https://onlinelibrary.wiley.com/doi/full/10.1111/codi.16239
- Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) — ClinicalTrials.gov (NCT04543994) — https://clinicaltrials.gov/study/NCT04543994
- Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues — U.S. Food and Drug Administration — https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products
Related Articles
- Clinical Applications
Stem Cell Therapy for Liver Cirrhosis
Early clinical trials suggest mesenchymal stem cell (MSC) infusions can improve liver function and, in one long-term study, survival in some cirrhosis patients, but no MSC product is FDA-approved for this use, and larger trials are still needed to confirm long-term benefit.
- Clinical Applications
Stem Cell Therapy for Diabetic Peripheral Neuropathy
Early human trials and a growing animal-study base suggest stem cell injections may improve nerve function in diabetic peripheral neuropathy, but the therapy remains experimental, unapproved by the FDA, and untested in large trials.
- Clinical Applications
Stem Cell Therapy for Endometriosis
Lab and animal studies suggest stem cells could one day calm the inflammation and lesion growth behind endometriosis, but the research is still confined to preclinical models — no human trials or approved treatments exist yet.